Proliferation News and Research

RSS

Interim data from multiple ongoing trials of XL147 PI3K inhibitor to be presented at ASCO 2010

Exelixis, Inc. today reported updated interim data from three ongoing trials of XL147 (SAR245408), a selective, orally available small molecule inhibitor of phosphoinositide-3-kinase (PI3K). Activation of the PI3K pathway is a frequent event in human tumors, promoting cell proliferation, survival, and resistance to chemotherapy and radiotherapy.

8 Jun 2010

CytRx granted U.S. Patent for bafetinib

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced the granting by the U.S. Patent and Trademark Office (USPTO) of U.S. Patent 7,728,131 for oncology drug candidate bafetinib, encompassing claims related to bafetinib's pharmaceutical compound and composition in all indications, as well as for use in methods for treating acute and chronic myelogenous leukemia and acute lymphoblastic leukemia.

7 Jun 2010

Exelixis reports updated interim data from trials of XL765 small molecule inhibitor of PI3K and mTOR

Exelixis, Inc. today reported updated interim data from three ongoing trials of XL765 (SAR245409), an orally available small molecule inhibitor of phosphoinositide-3-kinase (PI3K) and mTOR. Activation of the PI3K pathway is a frequent event in human tumors, promoting cell proliferation, survival, and resistance to chemotherapy and radiotherapy.

7 Jun 2010

AVEO's initiation of SCH 900105 Phase 2 trial in non-small cell lung cancer triggers $8.5M milestone payment

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it has initiated a Phase 2 clinical trial evaluating SCH 900105 (also referred to as AV-299) for the treatment of non-small cell lung cancer. The initiation of this trial triggers an $8.5 million milestone payment by Merck to AVEO resulting from a 2007 agreement between AVEO and Schering-Plough (now Merck).

7 Jun 2010

DOE program to develop new imager for improving reliability of cancer therapy using heavy-ion beams

In 2008 the Nuclear Science Division (NSD) of the U.S. Department of Energy's Lawrence Berkeley National Laboratory launched the Applied Nuclear Physics program, headed by NSD's Kai Vetter upon his return to Berkeley after six years with Lawrence Livermore National Laboratory. One of the goals of Applied Nuclear Physics is to take experimental principles and equipment created for basic research and develop them into tools that can address practical needs like cancer therapy and homeland security.

5 Jun 2010

Public should have SIRAD card to detect radioactive materials or monitor spills: Radiation expert

Radiation may be invisible, but it is very easy to measure. With current technology, people no longer need to live in dread of a lethal exposure to radiation in the event that the unthinkable happens.

4 Jun 2010

New therapy mounts double-barreled attack on leukemia, report UF researchers

A new therapy mounts a double-barreled attack on leukemia, targeting not just the cancer cells but also the environment in which those cells live and grow, University of Florida researchers report.

4 Jun 2010

New model reveals molecular basis of multiple hereditary exostoses

Children born with multiple hereditary exostoses (MHE) suffer from abnormal growths on their bones. These bony protrusions stunt their growth and can cause pain and disfigurement.

2 Jun 2010

GE Healthcare introduces new CESM technology to aid in breast cancer diagnosis

GE Healthcare, a pioneer in digital mammography, today announced the introduction of an innovative technology to aid in breast cancer diagnosis. GE Healthcare's new SenoBright Contrast Enhanced Spectral Mammography technology reduces ambiguity in mammography results, enabling physicians to detect and diagnose cancer with more confidence - even in the densest part of the breast tissue more rapidly and accurately.

1 Jun 2010

University of California scientists identify new kinase that regulates cell proliferation, migration

Scientists at the University of California, San Diego have identified a previously unknown kinase that regulates cell proliferation, shape and migration, and may play a major role in the progression or metastasis of cancer cells.

1 Jun 2010

CytRx commences Phase 2 clinical trial of bafetinib for high-risk B-cell chronic lymphocytic leukemia

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced initiation of a Phase 2 proof-of-concept clinical trial to evaluate the preliminary efficacy and safety of its oncology drug candidate bafetinib in patients with high-risk B-cell chronic lymphocytic leukemia (B-CLL).

29 May 2010

US HIFU acquires Sonatherm 600 medical device from Misonix

USHIFU, LLC (US HIFU), a world leader in minimally invasive high intensity focused ultrasound (HIFU) technologies and manufacturer of the Sonablate® 500 (Sonablate) medical device, announces the acquisition of certain Misonix HIFU assets and European distribution rights. In addition, through its transaction with Misonix, US HIFU acquires the Sonatherm® 600 medical device, a laparoscopic HIFU system used to ablate certain soft tissues.

29 May 2010

Low frequency ultrasound can heal and regenerate body tissues

When we think of ultrasound, it's usually imaging the inside of the body that springs to mind. However, while ultrasound imaging typically requires frequencies that are 50 to 2500 times higher than those human ear can detect, recent increasing evidence indicates that ultrasound at lower frequency can also be used to help certain body tissues to heal and regenerate. Now research that appears in Open Access Journal of Tissue Engineering published by SAGE-Hindawi suggests that ultrasound could also help tissue grafts to survive and thrive following surgery.

28 May 2010

OHSU partners with UO, Harvard to expedite research into compounds that may prevent Fanconi anemia

Oregon Health & Science University is partnering with the University of Oregon and Harvard Medical School to expedite basic science research into new and existing drugs and compounds that may prevent the complications associated with Fanconi anemia, an inherited condition that can lead to bone marrow failure and cancer.

28 May 2010

Positron Emission Mammography helps evaluate response to neoadjuvant chemotherapy: Study

In a recent study presented at the American Association of Cancer Research Annual Meeting in Washington, DC, researchers at the University of Texas MD Anderson Cancer Center showed that Positron Emission Mammography (PEM) helps evaluate response to neoadjuvant chemotherapy.

28 May 2010

Research findings offer possible applications in diagnosis and treatment of patients with atherosclerosis

Researchers from Boston University School of Medicine have shown that use of magnetic resonance imaging in an animal model can non-invasively identify dangerous plaques. The findings, which appear in the May issue of Circulation Cardiovascular Imaging, offer possible applications in the diagnosis and treatment of patients with atherosclerosis.

26 May 2010

Good number of natural bypass vessels an 'insurance policy' against blockage

When the arteries delivering oxygen to our vital organs are obstructed by atherosclerosis or clots, the result is almost always a stroke, heart attack or damage to a peripheral tissue such as the legs (peripheral artery disease). But the severity of tissue injury or destruction from a choked-off blood supply varies from person to person, and may depend in large part on whose circulatory system has the best back-up plan to provide alternate routes of circulation.

26 May 2010

UCSF scientists discover new stem cell in developing human brain

UCSF scientists have discovered a new stem cell in the developing human brain. The cell produces nerve cells that help form the neocortex - the site of higher cognitive function -- and likely accounts for the dramatic expansion of the region in the lineages that lead to man, the researchers say.

26 May 2010

Highlights from June 2010 issue of American Journal of Pathology

Dr. Kanneboyina Nagaraju and colleagues at the Children's National Medical Center, Washington, DC demonstrate that affected muscle may directly contribute to inflammation in muscular dystrophy. Their report can be found in the June 2010 issue of The American Journal of Pathology.

26 May 2010

Yissum introduces Dralgo platform to accelerate discovery of promising drug candidates

Drug discovery and development is a highly risky process, with only one in 10,000 initial candidate compounds reaching the market. When taking into account the aborted candidates, the cost of developing one successful drug may even reach $1 billion, and the development process may take as long as 15-20 years.

25 May 2010

Proliferation News and Research

Interim data from multiple ongoing trials of XL147 PI3K inhibitor to be presented at ASCO 2010

CytRx granted U.S. Patent for bafetinib

Exelixis reports updated interim data from trials of XL765 small molecule inhibitor of PI3K and mTOR

AVEO's initiation of SCH 900105 Phase 2 trial in non-small cell lung cancer triggers $8.5M milestone payment

DOE program to develop new imager for improving reliability of cancer therapy using heavy-ion beams

Public should have SIRAD card to detect radioactive materials or monitor spills: Radiation expert

New therapy mounts double-barreled attack on leukemia, report UF researchers

New model reveals molecular basis of multiple hereditary exostoses

GE Healthcare introduces new CESM technology to aid in breast cancer diagnosis

University of California scientists identify new kinase that regulates cell proliferation, migration

CytRx commences Phase 2 clinical trial of bafetinib for high-risk B-cell chronic lymphocytic leukemia

US HIFU acquires Sonatherm 600 medical device from Misonix

Low frequency ultrasound can heal and regenerate body tissues

OHSU partners with UO, Harvard to expedite research into compounds that may prevent Fanconi anemia

Positron Emission Mammography helps evaluate response to neoadjuvant chemotherapy: Study

Research findings offer possible applications in diagnosis and treatment of patients with atherosclerosis

Good number of natural bypass vessels an 'insurance policy' against blockage

UCSF scientists discover new stem cell in developing human brain

Highlights from June 2010 issue of American Journal of Pathology

Yissum introduces Dralgo platform to accelerate discovery of promising drug candidates

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News